|
Lifecore Biomedical Inc (NASDAQ: LFCR) |
|
Lifecore Biomedical Inc
LFCR's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Looking into Lifecore Biomedical Inc growth rates, revenue grew
by 7.1 % in II. Quarter 2024 from the same quarter a year ago.
Ranking at No. 53
Major Pharmaceutical Preparations industry recorded
growth of revenues by 6.17 %
Lifecore Biomedical Inc faced net loss in contrast to the net income a year ago in II. Quarter 2024
• More on LFCR's Growth
|
|
Lifecore Biomedical Inc realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 33.57 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 1.6.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.4.
• More on LFCR's Valuation
|
|
|
|
|
Lifecore Biomedical Inc realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 33.57 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 1.6.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.4.
Lifecore Biomedical Inc Price to Book Ratio is at 13.54 lower than Industry Avg. of 87.76. and higher than S&P 500 Avg. of 0.02
• More on LFCR's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com